Although many different types of protein transduction domains (‘PTD’) have been developed within the industry, the majority are virus composites or proteins derived from drosophilae. ForHuman Tech’s PTDs are human-based and boast higher transduction efficiency with no side-effects to date. The Company’s PTD-related products target autoimmune diseases through a variety of delivery techniques. One such immunosuppressant has been packaged and named “FHT-CT4,” a PTD conjugated with a recombinant bacterial protein that is shown to be effective with almost all autoimmune disorders, including asthma, rheumatoid arthritis and atomic dertatitis

Forhuman Tech has filed a provisional patent application in the US regarding the Transaction’s technology.

Concerning the Company’s PTD technology in general, the Company also has one patent registered in Korea and has filed
four international patent (PCT) applications currently being reviewed in Europe, Japan and the US.